IOL Chemicals Gets CEP Approval For Metformin Hydrochloride Process-II API
IOL Chemicals & Pharmaceuticals has obtained a Certificate of Suitability from the European Directorate for the Quality of Medicines & Health Care for its Metformin Hydrochloride Process-II API. This regulatory approval complements the company's existing valid certificate for Metformin Hydrochloride, enhancing its manufacturing capabilities for this critical antidiabetic medication and strengthening its position in European pharmaceutical markets.
*this image is generated using AI for illustrative purposes only.
IOL Chemicals & Pharmaceuticals has secured an important regulatory milestone with the European Directorate for the Quality of Medicines & Health Care (EDQM) granting a Certificate of Suitability (CEP) for its API product Metformin Hydrochloride Process-II. This achievement expands the company's regulatory portfolio for this critical antidiabetic medication.
Regulatory Certification Details
The EDQM certification represents a significant regulatory approval for IOL Chemicals & Pharmaceuticals' manufacturing processes. The company disclosed that this new CEP comes in addition to an existing valid certificate already held for Metformin Hydrochloride, indicating the company now has multiple approved processes for manufacturing this important pharmaceutical ingredient.
| Parameter: | Details |
|---|---|
| Certification Body: | European Directorate for the Quality of Medicines & Health Care (EDQM) |
| Product: | Metformin Hydrochloride Process-II |
| Certificate Type: | Certificate of Suitability (CEP) |
| Additional Certification: | Existing valid CEP for Metformin Hydrochloride |
Product Significance
Metformin Hydrochloride serves as a crucial antidiabetic drug used to manage high blood sugar levels in diabetes patients. The availability of multiple certified manufacturing processes for this API demonstrates IOL Chemicals & Pharmaceuticals' commitment to ensuring reliable supply and manufacturing flexibility for this essential medication.
Regulatory Compliance
The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure ensures transparency with stakeholders and regulatory authorities regarding this significant regulatory achievement.
Strategic Impact
This additional EDQM certification strengthens IOL Chemicals & Pharmaceuticals' position in the pharmaceutical API market, particularly for diabetes management medications. Having multiple approved processes for Metformin Hydrochloride production provides the company with enhanced manufacturing capabilities and regulatory compliance across European markets.
Historical Stock Returns for IOL Chemicals & Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.37% | -0.05% | -3.48% | -23.66% | +12.96% | -44.06% |
20
